NEWTON, Mass.--(BUSINESS WIRE)-- Galectin Therapeutics (OTC:GALT.ob - News), the leading developer of galectin inhibitor therapeutic compounds to treat fibrosis and cancer, today announced the election of Dr. Marc Rubin to its Board of Directors, effective today. Titan Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of products for the treatment of central nervous system diseases. Dr. Rubin, Executive Chairman of Titan Pharmaceuticals, replaced S. Colin Neill who resigned from Galectin Therapeutics’ Board, effective October 11, 2011.
“We are very pleased to have Dr. Rubin join our Board of Directors,” said James C. Czirr, Executive Chairman of the Board of Directors, Galectin Therapeutics. “Marc is a highly regarded executive with a wealth of drug development and business experience. His expertise will be invaluable as we execute our plan to commercialize our fibrosis and cancer compounds and enter into partnerships for sales and distribution.”
“I believe Galectin Therapeutics offers the potential to be the leader in developing and commercializing galectin-targeted drugs to treat fibrosis and cancer,” said Dr. Rubin. “I am excited to be a part of a team that is focused on developing novel compounds to treat unmet medical needs such as liver fibrosis, a disease with no current treatment option except liver transplantation. Galectin Therapeutics candidates have demonstrated the ability to arrest and reverse liver fibrosis in pre-clinical studies.”